Multiple Myeloma

TORONTO, Ontario — November 13, 2025: Telo Genomics announced it will present its groundbreaking individual-cell MRD risk-assessment technology at...

Princeton, N.J., September 22, 2025 – Bristol Myers Squibb (BMS) announced that its investigational cereblon E3 ligase modulator (CELMoD™)...